D. Boral Capital Reaffirms Buy Rating for Carisma Therapeutics (NASDAQ:CARM)

D. Boral Capital restated their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM) in a report released on Monday,Benzinga reports. The firm currently has a $12.00 target price on the stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Robert W. Baird lowered Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $10.00 to $1.00 in a research note on Thursday, December 12th. BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Baird R W lowered Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Carisma Therapeutics presently has a consensus rating of “Hold” and an average target price of $4.94.

Carisma Therapeutics Trading Down 2.0 %

NASDAQ:CARM opened at $0.45 on Monday. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The firm has a market capitalization of $18.60 million, a price-to-earnings ratio of -0.29 and a beta of 1.56. Carisma Therapeutics has a one year low of $0.38 and a one year high of $2.77. The business has a fifty day moving average price of $0.67 and a 200-day moving average price of $0.92.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). The firm had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. Sell-side analysts forecast that Carisma Therapeutics will post -1.32 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wexford Capital LP boosted its holdings in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Carisma Therapeutics in the 2nd quarter valued at about $40,000. Finally, Barclays PLC lifted its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. Institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.